Inhibitors of SecA, and methods of making and using thereof, are described herein. The compounds described herein can be used to treat or prevent microbial infections, such as bacterial infections.

Inhibitors of SecA, and methods of making and using thereof, are described herein. The compounds described herein can be used to treat or prevent microbial infections, such as bacterial infections.

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

##STR00001##

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

##STR00001##

To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology improvement in a power generation layer, and whereby short circuit current (Jsc) attenuation when irradiating light is simultaneously suppressed, and an organic solar cell using the same. An organic photoelectric conversion element having: a transparent first electrode; a power generation layer having a p-type organic semiconductor material and an n-type organic semiconductor material; and a second electrode, on a transparent substrate, in which the power generation layer is a bulk heterojunction power generation layer including the p-type organic semiconductor material and the n-type organic semiconductor material, and additionally includes a compound represented by either the following general formula (I) or general formula (II). ##STR00001##

To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology improvement in a power generation layer, and whereby short circuit current (Jsc) attenuation when irradiating light is simultaneously suppressed, and an organic solar cell using the same. An organic photoelectric conversion element having: a transparent first electrode; a power generation layer having a p-type organic semiconductor material and an n-type organic semiconductor material; and a second electrode, on a transparent substrate, in which the power generation layer is a bulk heterojunction power generation layer including the p-type organic semiconductor material and the n-type organic semiconductor material, and additionally includes a compound represented by either the following general formula (I) or general formula (II). ##STR00001##

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group, n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group. ##STR00001##

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.